The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers

Molecular Therapy

Volumn 20, Issue 4, 2012, Pages 749-758

  Parato, Kelley A ^a   Breitbach, Caroline J ^b   Le Boeuf, Fabrice ^a   Wang, Jiahu ^a,b   Storbeck, Chris ^a,b   Ilkow, Carolina ^a   Diallo, Jean Simon ^a   Falls, Theresa ^a   Burns, Joseph ^a   Garcia, Vanessa ^a   Kanji, Femina ^a   Evgin, Laura ^a,c   Hu, Kang ^a,b   Paradis, Francois ^a   Knowles, Shane ^a   Hwang, Tae Ho ^d   Vanderhyden, Barbara C ^a,c   Auer, Rebecca ^a,c   Kirn, David H ^b   Bell, John C ^a,b,c  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^b Jennerex Biotherapeutics Inc   (United States)

^c UNIVERSITY OF OTTAWA   (Canada)

^d Pusan National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON; JX 594; ONCOLYTIC POXVIRUS JX 594; ONCOLYTIC VIRUS; RAS PROTEIN; THYMIDINE KINASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN CANCER; CANCER CELL; CLINICAL ARTICLE; COLON CANCER; COLORECTAL CANCER; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; DRUG EFFICACY; DRUG MECHANISM; ENDOMETRIUM CANCER; ENZYME INHIBITION; FEMALE; GENE ACTIVATION; GENE EXPRESSION; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; JX 594 GENE; KIDNEY CANCER; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; OVARY CANCER; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; VIRUS GENE; VIRUS REPLICATION; VULVA CANCER;

MURINAE; POXVIRIDAE; VACCINIA VIRUS;

EID: 84859443203     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2011.276     Document Type: Article

References (47)

1. Parato, KA, Lichty, BD and Bell, JC (2009). Diplomatic immunity: turning a foe into an ally. Curr Opin Mol Ther 11: 13-21.
2. Cattaneo, R, Miest, T, Shashkova, EV and Barry, MA (2008). Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded. Nat Rev Microbiol 6: 529-540. (Pubitemid 351850977)
3. Bell, JC, Lichty, B and Stojdl, D (2003). Getting oncolytic virus therapies off the ground. Cancer Cell 4: 7-11. (Pubitemid 36904156)
4. Liu, TC, Hwang, TH, Bell, JC and Kirn, DH (2008). Development of targeted oncolytic virotherapeutics through translational research. Expert Opin Biol Ther 8: 1381-1391.
5. Liu, TC, Galanis, E and Kirn, D (2007). Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress. Nat Clin Pract Oncol 4: 101-117. (Pubitemid 46189539)
6. Stojdl, DF, Lichty, B, Knowles, S, Marius, R, Atkins, H, Sonenberg, N et al. (2000). Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med 6: 821-825. (Pubitemid 30469434)
7. Stojdl, DF, Lichty, BD, tenOever, BR, Paterson, JM, Power, AT, Knowles, S et al. (2003). VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell 4: 263-275. (Pubitemid 37329791)
8. Coffey, MC, Strong, JE, Forsyth, PA and Lee, PW (1998). Reovirus therapy of tumors with activated Ras pathway. Science 282: 1332-1334. (Pubitemid 28524498)
9. Norman, KL and Lee, PW (2000). Reovirus as a novel oncolytic agent. J Clin Invest 105: 1035-1038. (Pubitemid 30217685)
10. Bischoff, JR, Kirn, DH, Williams, A, Heise, C, Horn, S, Muna, M et al. (1996). An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 274: 373-376. (Pubitemid 26353341)
11. Heise, C, Hermiston, T, Johnson, L, Brooks, G, Sampson-Johannes, A, Williams, A et al. (2000). An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy. Nat Med 6: 1134-1139.
12. Peng, KW, TenEyck, CJ, Galanis, E, Kalli, KR, Hartmann, LC and Russell, SJ (2002). Intraperitoneal therapy of ovarian cancer using an engineered measles virus. Cancer Res 62: 4656-4662.
13. Grote, D, Russell, SJ, Cornu, TI, Cattaneo, R, Vile, R, Poland, GA et al. (2001). Live attenuated measles virus induces regression of human lymphoma xenografts in immunodeficient mice. Blood 97: 3746-3754.
14. Mineta, T, Rabkin, SD, Yazaki, T, Hunter, WD and Martuza, RL (1995). Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med 1: 938-943.
15. Mineta, T, Rabkin, SD and Martuza, RL (1994). Treatment of malignant gliomas using ganciclovir-hypersensitive, ribonucleotide reductase-deficient herpes simplex viral mutant. Cancer Res 54: 3963-3966. (Pubitemid 24258091)
16. Kirn, DH and Thorne, SH (2009). Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer. Nat Rev Cancer 9: 64-71.
17. Chung, CS, Hsiao, JC, Chang, YS and Chang, W (1998). A27L protein mediates vaccinia virus interaction with cell surface heparan sulfate. J Virol 72: 1577-1585. (Pubitemid 28116945)
18. Laliberte, JP and Moss, B (2009). Appraising the apoptotic mimicry model and the role of phospholipids for poxvirus entry. Proc Natl Acad Sci USA 106: 17517-17521.
19. Mastrangelo, MJ, Maguire, HC Jr, Eisenlohr, LC, Laughlin, CE, Monken, CE, McCue, PA et al. (1999). Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma. Cancer Gene Ther 6: 409-422. (Pubitemid 129667814)
20. Kim, JH, Oh, JY, Park, BH, Lee, DE, Kim, JS, Park, HE et al. (2006). Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF. Mol Ther 14: 361-370. (Pubitemid 44184970)
21. Dranoff, G, Jaffee, E, Lazenby, A, Golumbek, P, Levitsky, H, Brose, K et al. (1993). Vaccination with irradiated tumor cells engineered to secrete murine granulocytemacrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 90: 3539-3543. (Pubitemid 23111402)
22. Park, BH, Hwang, T, Liu, TC, Sze, DY, Kim, JS, Kwon, HC et al. (2008). Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial. Lancet Oncol 9: 533-542.
23. Breitbach, CJ, Burke, J, Jonker, D, Stephenson, J, Haas, AR, Chow, LQ et al. (2011). Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Nature 477: 99-102.
24. McCart, JA, Ward, JM, Lee, J, Hu, Y, Alexander, HR, Libutti, SK et al. (2001). Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes. Cancer Res 61: 8751-8757. (Pubitemid 34013887)
25. Thorne, SH, Hwang, TH, O'Gorman, WE, Bartlett, DL, Sei, S, Kanji, F et al. (2007). Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963. J Clin Invest 117: 3350-3358. (Pubitemid 350096991)
26. Kirn, DH, Wang, Y, Le Boeuf, F, Bell, J and Thorne, SH (2007). Targeting of interferonbeta to produce a specific, multi-mechanistic oncolytic vaccinia virus. PLoS Med 4: e353.
27. Foloppe, J, Kintz, J, Futin, N, Findeli, A, Cordier, P, Schlesinger, Y et al. (2008). Targeted delivery of a suicide gene to human colorectal tumors by a conditionally replicating vaccinia virus. Gene Ther 15: 1361-1371.
28. Zhang, Q, Liang, C, Yu, YA, Chen, N, Dandekar, T and Szalay, AA (2009). The highly attenuated oncolytic recombinant vaccinia virus GLV-1h68: comparative genomic features and the contribution of F14.5L inactivation. Mol Genet Genomics 282: 417-435.
29. Hengstschläer, M, Pfeilstöker, M and Wawra, E (1998). Thymidine kinase expression. A marker for malignant cells. Adv Exp Med Biol 431: 455-460.
30. Luker, KE, Hutchens, M, Schultz, T, Pekosz, A and Luker, GD (2005). Bioluminescence imaging of vaccinia virus: effects of interferon on viral replication and spread. Virology 341: 284-300. (Pubitemid 41417785)
31. Connolly, DC, Bao, R, Nikitin, AY, Stephens, KC, Poole, TW, Hua, X et al. (2003). Female mice chimeric for expression of the simian virus 40 TAg under control of the MISIIR promoter develop epithelial ovarian cancer. Cancer Res 63: 1389-1397. (Pubitemid 36348722)
32. Yang, H, Kim, SK, Kim, M, Reche, PA, Morehead, TJ, Damon, IK et al. (2005). Antiviral chemotherapy facilitates control of poxvirus infections through inhibition of cellular signal transduction. J Clin Invest 115: 379-387. (Pubitemid 40385479)
33. Brown, JP, Twardzik, DR, Marquardt, H and Todaro, GJ (1985). Vaccinia virus encodes a polypeptide homologous to epidermal growth factor and transforming growth factor. Nature 313: 491-492. (Pubitemid 15153167)
34. Alcami, A and Efstathiou, S (2000). Soluble chemokine binding proteins are also encoded by herpesviruses. Immunol Today 21: 526-527.
35. Langhammer, S, Koban, R, Yue, C and Ellerbrok, H (2011). Inhibition of poxvirus spreading by the anti-tumor drug Gefitinib (Iressa). Antiviral Res 89: 64-70.
36. Buller, RM, Smith, GL, Cremer, K, Notkins, AL and Moss, B (1985). Decreased virulence of recombinant vaccinia virus expression vectors is associated with a thymidine kinase-negative phenotype. Nature 317: 813-815. (Pubitemid 16195408)
37. Eramo, A, Lotti, F, Sette, G, Pilozzi, E, Biffoni, M, Di Virgilio, A et al. (2008). Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ 15: 504-514. (Pubitemid 351267301)
38. Li, D, Xie, K, Wolff, R and Abbruzzese, JL (2004). Pancreatic cancer. Lancet 363: 1049-1057. (Pubitemid 38410779)
39. Pao, W, Wang, TY, Riely, GJ, Miller, VA, Pan, Q, Ladanyi, M et al. (2005). KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2: e17.
40. Yazdi, AS, Palmedo, G, Flaig, MJ, Puchta, U, Reckwerth, A, Rütten, A et al. (2003). Mutations of the BRAF gene in benign and malignant melanocytic lesions. J Invest Dermatol 121: 1160-1162. (Pubitemid 37430987)
41. Walther, A, Johnstone, E, Swanton, C, Midgley, R, Tomlinson, I and Kerr, D (2009). Genetic prognostic and predictive markers in colorectal cancer. Nat Rev Cancer 9: 489-499.
42. Giaccone, G and Wang, Y (2011). Strategies for overcoming resistance to EGFR family tyrosine kinase inhibitors. Cancer Treat Rev 37: 456-464.
43. Amado, RG, Wolf, M, Peeters, M, Van Cutsem, E, Siena, S, Freeman, DJ et al. (2008). Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26: 1626-1634.
44. Douglas, JT, Kim, M, Sumerel, LA, Carey, DE and Curiel, DT (2001). Efficient oncolysis by a replicating adenovirus (ad) in vivo is critically dependent on tumor expression of primary ad receptors. Cancer Res 61: 813-817. (Pubitemid 32174383)
45. Weislow, OS, Kiser, R, Fine, DL, Bader, J, Shoemaker, RH and Boyd, MR (1989). New soluble-formazan assay for HIV-1 cytopathic effects: application to high-flux screening of synthetic and natural products for AIDS-antiviral activity. J Natl Cancer Inst 81: 577-586. (Pubitemid 19104488)
46. Eramo, A, Lotti, F, Sette, G, Pilozzi, E, Biffoni, M, Di Virgilio, A et al. (2008). Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ 15: 504-514. (Pubitemid 351267301)
47. Ricci-Vitiani, L, Lombardi, DG, Pilozzi, E, Biffoni, M, Todaro, M, Peschle, C et al. (2007). Identification and expansion of human colon-cancer-initiating cells. Nature 445: 111-115. (Pubitemid 46067311)